TCGX to Take Migraine Drug Developer TriGemX Public in $246M De-SPAC With $160M PIPE
TCGX sits 20% above its 52-week low of $10.3.
Summary
TCGX signed a definitive business combination with TriGemX Bio, the developer of elismetrep, an oral TRPM8 blocker in Phase 3 for acute migraine, and the combined company is to be named TriGemX Bio and is expected to trade on Nasdaq under the ticker symbol TGEM. The deal brings roughly $246M of gross proceeds assuming no redemptions: about $86M from TCGX's trust plus a $160M PIPE priced at $10.00 a share from healthcare specialists including Viking Global, ADAR1, BVF, Samsara and Vianti. That capital is earmarked to finish the two pivotal Phase 3 trials and a long-term safety study, file an NDA, run a prevention trial, and build commercial readiness. Post-transaction equity value is pegged at about $600M, with TriGemX holders rolling 100% of their equity and taking no cash; TriGemX carries a $361M pre-money equity value, and closing requires at least $150M available closing cash, with up to 539,062 founder shares forfeited if it is below $161M. This follows the August 8-K on TCGX's ~$91.5M IPO raise and the September filing for a separate $100M SPAC II, so the sponsor is now putting its first vehicle to work. The key risk is redemption: the $246M headline shrinks dollar-for-dollar if public holders cash out, and closing is targeted for Q1 2027 pending shareholder votes. First Phase 3 data is expected mid-2027.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — TriGemX pre-money equity value is $361M; closing requires at least $150M available closing cash, and up to 539,062 founder shares are forfeited if it is below $161M.
At the time of this announcement, TCGX was trading at $12.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $139M. The 52-week trading range was $10.30 to $18.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.